Corcept Therapeutics (CORT) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue rose 64% year over year to $340.5 million, topping the consensus estimate of roughly $323.9 million.
• Adjusted earnings per share (EPS) came in at $1.01, beating analyst expectations of $0.79 by $0.22.
• The Korlym franchise and its authorized generic generated $249.1 million, while newly launched Lifyorli contributed $91.4 million in product revenue.
• Net income surged to $126.8 million, or $1.01 per diluted share, from $19.7 million, or $0.16 per share, a year earlier.
• Management reiterated full-year 2026 revenue guidance of $1.1 billion to $1.2 billion, a move that left some investors underwhelmed.
• Cash and investments climbed to $662.3 million as of September 30, 2026.
• For more information on CORT's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages dedicated to the ticker.
• Explore Trending AI Robots to see AI-driven trading strategies currently drawing attention in the market.

Earnings Context and Why It Matters

Corcept Therapeutics has been in the midst of a pivotal commercial transition. Its endocrinology franchise, built around Korlym for Cushing's syndrome, has delivered steady growth, but the company's biggest story in 2026 is Lifyorli (relacorilant), launched April 1 as a treatment for platinum-resistant ovarian cancer. This quarter offers investors a first meaningful look at how quickly the oncology launch is scaling and whether the company can sustain its momentum across two franchises. With a December decision date pending for an expanded relacorilant indication, the results carry weight well beyond a single quarter, shaping expectations for the company's multi-year growth trajectory.

Reported Results

Corcept Therapeutics reported its third quarter 2026 results, for the period ended September 30, 2026, on November 3, 2026. Total product revenue reached $340.5 million, a 64% increase from $207.6 million in the same period of 2025 and above the analyst consensus of approximately $323.9 million.

Adjusted EPS was $1.01, beating the consensus estimate of $0.79 by $0.22. On a generally accepted accounting principles (GAAP) basis, net income climbed to $126.8 million, or $1.01 per diluted share, compared with $19.7 million, or $0.16 per diluted share, in the prior-year quarter.

Revenue growth was driven by both franchises. Korlym and its authorized generic product generated $249.1 million, while Lifyorli contributed $91.4 million in its second full quarter on the market. Management reiterated full-year 2026 revenue guidance of $1.1 billion to $1.2 billion, with the midpoint slightly above the consensus of roughly $1.14 billion. Cash and investments totaled $662.3 million at quarter-end, up from $544.6 million three months earlier.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves like Corcept Therapeutics' quarterly results, the AI Screener offers a practical way to identify comparable setups across the healthcare sector.

Market Reaction and Investor Sentiment

Despite the top- and bottom-line beats, Corcept shares slipped about 3.9% in after-hours trading following the report. The primary driver was the company's decision to reiterate, rather than raise, its full-year revenue guidance. Investors had grown accustomed to upward revisions, particularly after the prior quarter's strong results and the rapid early uptake of Lifyorli. The reaffirmed range of $1.1 billion to $1.2 billion signaled confidence in the existing trajectory but fell short of the more aggressive outlook some shareholders were hoping for, underscoring how elevated expectations had become heading into the print.

Forward Outlook and Key Factors to Monitor

The most immediate catalyst for Corcept is the FDA's (Food and Drug Administration's) decision on its resubmitted New Drug Application (NDA) for relacorilant in Cushing's syndrome, expected by December 17, 2026. An approval would broaden relacorilant's label and could meaningfully expand its addressable market in endocrinology.

On the oncology side, investors will track the continued ramp of Lifyorli, including patient growth and reimbursement dynamics. The company also reported positive results from its BELLA Part A Phase 2 trial in platinum-resistant ovarian cancer, with additional readouts across the broader relacorilant development program expected in the coming quarters.

Beyond oncology and endocrinology, data from the Phase 2b MONARCH study of miricorilant in MASH (metabolic dysfunction-associated steatohepatitis) and the planned Phase 3 trial of dazucorilant in ALS (amyotrophic lateral sclerosis) represent longer-horizon value drivers. Cost discipline, margin trends, and the pace of cash generation will also remain in focus as Corcept funds a broad clinical pipeline while commercializing two franchises.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations